GH:NSD-Guardant Health Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 25.08

Change

-0.01 (-0.04)%

Market Cap

USD 3.30B

Volume

2.60M

Analyst Target

USD 110.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-0.97 (-0.19%)

USD 41.20B
ICLR ICON PLC

+9.91 (+3.39%)

USD 24.84B
ILMN Illumina Inc

+0.76 (+0.58%)

USD 20.58B
NTRA Natera Inc

-0.11 (-0.09%)

USD 15.65B
EXAS EXACT Sciences Corporation

+1.22 (+1.79%)

USD 11.40B
MEDP Medpace Holdings Inc

+6.64 (+1.87%)

USD 10.90B
RDNT RadNet Inc

+0.30 (+0.45%)

USD 5.01B
SHC Sotera Health Co

+0.08 (+0.48%)

USD 4.76B
NEOG Neogen Corporation

+0.37 (+2.19%)

USD 3.50B
TWST Twist Bioscience Corp

-0.65 (-1.36%)

USD 2.75B

ETFs Containing GH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.28% 51% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.28% 51% F 40% F
Trailing 12 Months  
Capital Gain -8.53% 52% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.53% 52% F 38% F
Trailing 5 Years  
Capital Gain -66.08% 41% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.08% 41% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -12.12% 40% F 24% F
Dividend Return -12.12% 38% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.63% 56% F 35% F
Risk Adjusted Return -23.48% 42% F 27% F
Market Capitalization 3.30B 79% B- 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector